Multiple sclerosis (MS) remains a formidable neurological challenge, affecting more than 2.8 million people worldwide, including approximately 1 million in the United States. Despite available immune-modulating therapies, many patients experience worsening disability due to underlying neurodegeneration and myelin damage. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing LUCID-MS, a patented therapeutic candidate designed to address this unmet need by directly protecting or restoring myelin integrity, potentially improving mobility and bodily function.
On June 9, 2026, Quantum BioPharma announced the completion of Phase 1 clinical studies involving healthy volunteers. The therapy demonstrated a favorable safety profile and was generally well tolerated, marking an important step forward. In April 2026, the company reached a significant milestone by submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for LUCID-MS.
The LUCID-MS program focuses on the core problem of demyelination in MS, where the immune system attacks the protective myelin sheath surrounding nerve fibers in the brain and spinal cord. This disruption leads to symptoms such as loss of mobility and coordination. Current treatments primarily reduce inflammation and relapse frequency but may not adequately halt disease progression. LUCID-MS aims to provide neuroprotection and remyelination, potentially altering the disease trajectory.
The completion of Phase 1 studies and IND submission represent critical regulatory steps toward clinical development. If successful, LUCID-MS could offer a new therapeutic option for MS patients who continue to face disability progression. The company’s focus on myelin repair distinguishes it from many existing therapies, addressing a key driver of long-term decline.
Investors and stakeholders can find the latest updates on Quantum BioPharma in the company’s newsroom at https://ibn.fm/QNTM. Forward-looking statements in the announcement are subject to risks and uncertainties detailed in the company’s SEC filings, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
The implications of this advancement are significant for the MS community. With nearly 1 million patients in the U.S. alone, an effective remyelinating therapy could improve quality of life and reduce disability burden. While Phase 1 results are promising, further trials will be necessary to confirm efficacy and long-term safety. Quantum BioPharma’s progress underscores the ongoing pursuit of disease-modifying treatments that go beyond symptom management.
